Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2023-05-18 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司2022年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度持续督导跟踪报告" (2022 Annual Continuous Supervision Follow-up Report) issued by 中信证券股份有限公司 as the sponsor for 北京神州细胞生物技术集团股份公司. It references regulatory frameworks such as the China Securities Regulatory Commission and Shanghai Stock Exchange rules, and details ongoing supervision activities, risk disclosures, financial data, and operational updates for the year 2022. The content is comprehensive, covering management oversight, risk factors, financial performance, and R&D progress, consistent with a detailed regulatory or supervisory report rather than a simple announcement or presentation. It is not an annual report (10-K) but a specialized continuous supervision report required by securities regulations for companies listed on the Shanghai Stock Exchange STAR Market (科创板). This type of document is typically classified as an Audit Report / Information (AR) because it involves regulatory compliance, ongoing monitoring, and detailed disclosures related to the company's operations and risks, but is not a full annual report. The document length (15,000 characters) and detailed content confirm it is a substantive report, not a brief announcement or certification. Therefore, the best fitting category is AR (Audit Report / Information). FY 2022
2023-05-18 Chinese
北京市金杜律师事务所关于北京神州细胞生物技术集团股份公司2022年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2022 Annual General Meeting (AGM) of Beijing Shenzhou Cell Technology Group Co., Ltd. It details the procedures of the AGM, the qualifications of attendees, the voting process, and the results of the shareholder votes on various proposals including the 2022 annual report, financial statements, profit distribution, and other corporate matters. The document does not contain the actual annual report or financial statements but rather confirms the legality and validity of the AGM process and voting outcomes. This type of document is a legal opinion related to the AGM and the voting results, not the report itself. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (8434 characters) and content support this classification with high confidence.
2023-05-16 Chinese
神州细胞2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as an announcement of the resolutions from the 2022 Annual General Meeting (AGM) of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the date and location of the meeting, attendance, voting results on various proposals including the 2022 annual report, financial statements, board and supervisory reports, profit distribution, remuneration plans, auditor appointment, and capital changes. The document is a formal announcement of the voting results from the AGM, not the full annual report or any other detailed report itself. It includes detailed voting outcomes and legal attestations confirming the validity of the meeting and votes. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 4942 characters, which is sufficient to include detailed voting results rather than a brief report publication announcement. Hence, the classification is DVA with high confidence.
2023-05-16 Chinese
神州细胞自愿披露关于控股子公司新冠疫苗SCTV01E国内III期临床研究最终分析主要结果的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the final analysis results of the Phase III clinical trial of their COVID-19 vaccine candidate SCTV01E. It provides detailed clinical trial results, safety and efficacy data, product information, and risk warnings. The document is an announcement of clinical trial results and related information rather than a financial report, regulatory filing, or management report. It does not contain financial statements or typical financial reporting content. It is also not a report publication announcement since it contains substantive content rather than just a notice of report availability. The document fits best into the category of Regulatory Filings (RNS) as it is a general regulatory announcement about clinical trial results and risk disclosures that do not fit other specific categories.
2023-05-12 Chinese
神州细胞2022年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2022 年年度股东大会会议资料" which translates to "2022 Annual General Meeting (AGM) Materials" for Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It contains detailed information about the AGM including meeting notices, agenda, proposals to be voted on, and supporting reports such as the board of directors' report, supervisory board report, financial reports, and other related documents. The content is consistent with materials prepared and distributed for an Annual General Meeting to shareholders. It is not the annual report itself but the meeting materials for the AGM. Therefore, the document fits the category of AGM Information (AGM-R). The document length is substantial (15,000 characters), indicating it is the full meeting materials, not just an announcement or a brief notice.
2023-05-05 Chinese
神州细胞向特定对象发行部分限售股上市流通公告
Share Issue/Capital Change Classification · 100% confidence The document is an announcement regarding the listing and circulation of restricted shares that were previously subject to a lock-up period. It details the number of shares becoming freely tradable, the shareholders involved, and confirms compliance with relevant securities laws and regulations. There is no financial statement or detailed financial analysis present, nor is this a report or presentation. The document is a formal disclosure about the change in share status, specifically the unlocking and listing of restricted shares. This fits the category of Share Issue/Capital Change announcements, as it concerns the change in capital structure due to the release of restricted shares for trading.
2023-04-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.